The company reported a profit of 5.2 million Australian dollars ($3.4 million) on AU$502.5 million ($332.5 million) in revenue last year, according to filings.
Market Conditions and Comparisons
The canceled listing comes as IPOs are generally rising, but the market is still beset by starts and stops. Aluminum recycling giant Novelis Inc. and online casino games developer Games Global canceled or postponed IPOs over the past month, citing market conditions.
Separately, artificial intelligence-powered diagnostics firm Tempus AI Inc. priced a $411 million IPO at the top of its range on Thursday and saw shares rally in debut trading Friday.
Telix Pharmaceuticals Pulls US IPO : Confidential Plans and Future Prospects
Telix submitted confidential plans for a U.S. IPO in January with the U.S. Securities and Exchange Commission. Since then, the company said it has achieved commercially significant milestones on its drug candidates, plus several strategic acquisitions.
Telix has also filed for additional approvals with the U.S. Food and Drug Administration. Telix also said it plans on expanding its U.S. commercial team to eventually launch new products Zircaix, Pixclara, and a drug called TLX007-CDx targeting prostate cancer.
